Shire achieved positive results from its first Phase III study (TKT032) evaluating the safety and efficacy of velaglucerase alfa, an investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. Data from a pediatric study and five-year follow-up results from a long-term Phase I/II extension study (TKT025 EXT) in adults also support long-term safety and efficacy of velaglucerase alfa in patients with Type 1 Gaucher disease. Both studies (TKT032 and TKT025 EXT) met their...